Chronic Kidney Disease in Dogs: Welfare and Management
Disease Overview
Chronic kidney disease (CKD) involves progressive, irreversible damage to kidney nephrons over months to years. It is most common in dogs over 7 years. Causes include chronic pyelonephritis, glomerulonephritis, inherited nephropathies (certain breeds), toxin exposure, and end-stage renal disease following acute kidney injury. IRIS staging (I-IV) based on creatinine, SDMA, and proteinuria guides prognosis and management.
Welfare Consequences
CKD causes accumulation of uraemic toxins causing nausea, vomiting, reduced appetite, weight loss, lethargy, and weakness. Anaemia of chronic kidney disease causes exercise intolerance and further reduces quality of life. Hypertension (common secondary to CKD) causes ocular haemorrhage, retinal detachment, and neurological signs. Advanced CKD causes uraemic encephalopathy, uraemic ulcers, and profound suffering.
Diagnosis and Staging
Early detection through annual biochemistry and urinalysis in older dogs allows intervention before significant clinical signs develop. Creatinine and SDMA (symmetric dimethylarginine, a sensitive early marker) indicate GFR. Urine specific gravity, urine protein:creatinine ratio (UPC), and blood pressure measurement complete staging. IRIS stage II-III dogs may have minimal clinical signs but benefit from management interventions.
Dietary and Medical Management
Renal diets (reduced phosphorus, reduced protein, added omega-3 fatty acids, increased energy density) slow CKD progression and reduce uraemic signs. Phosphorus binders (aluminium hydroxide, calcium carbonate, lanthanum carbonate) reduce intestinal phosphorus absorption. Anti-nausea medications (maropitant, ondansetron) improve appetite and comfort. ACE inhibitors or ARBs reduce proteinuria and systemic hypertension. Subcutaneous fluid therapy supports hydration in advanced disease.
Quality of Life and Monitoring
Regular monitoring (4-8 weekly in advanced stages) allows adjustment of management and early recognition of decompensation. Daily home monitoring of appetite, water intake, vomiting, and activity level by owners provides valuable welfare data. Quality of life scales (HHHHHMM, Zoetis QoL tool) help quantify welfare status. Open discussion with owners about the progressive nature of CKD and palliative care options ensures compassionate end-of-life decisions.